Pivotal Life Sciences — Full Portfolio

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.

BiotechDeep TechHealthtechSouth San Francisco, US

Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Board seatRHRob Hopfner· per SEC Form D

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesJAJanus Henderson InvestorsLOLongitude Capital+4 more

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

LBLyn Baranowski(CEO)in

Co-investorsANAndera PartnersCACatalio Capital Management, LPF-F-Prime CapitalINInVivium CapitalNONorwest Venture PartnersRIRiverVest Venture Partners+9 more

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

KFKristen Fortney, PhD(Co-Founder, CEO)EMEric Morgen, MD(Co-Founder, COO)KFKristen Fortney(Founder)inEMEric Morgen(Founder)inDGDov Goldstein(Executive Officer)in

BoardPEPatrick Enright(Director)in

Co-investorsANAndreessen HorowitzELElad GilFEFelicis VenturesGRGreen Sands EquityIAIA Seed VenturesLOLongitude Capital+18 more

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

DEDr. Edgar G. Engleman(Founder)

Co-investorsPFPfizer Venture InvestmentsRARA CapitalSASamsara BioCapitalSOSofinnova VenturesVIVivo CapitalNANan Fung Life Sciences+3 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)SASamsara BioCapital+3 more

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)JOJoshua Ofman, MD, MSHS(Chief Executive Officer)inAFAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)JCJennifer Cook(Executive Officer, Director)inRichard Klausner(Director)

Co-investorsAMAmino CapitalARARCH Venture PartnersBEBezos ExpeditionsBLBluebird VenturesDEDecheng CapitalDEDentsu Ventures+13 more

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.

BiotechHealthtechMedical DevicesNorthbrook, US

JAJeffrey Aronin(Director)inJMJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)

BoardARAaron Royston(Director)in

Co-investorsAIAisling CapitalHBHBM Healthcare InvestmentsHBHBM PartnersPAParagon Biosciences LLCVAValor Equity PartnersVEvenBio Partners+3 more

Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder.

BiotechDigital HealthHealthtechMental HealthToronto, CA

ESEric So(Co-Founder, Executive Chairman)inJKJohn Kanakis(Co-Founder)inPGPaul Glavine(Co-Founder and Chief Growth Officer)inGabriel Fahel(Executive Officer)Douglas Drysdale(Executive Officer)Jacqueline Poriadjian(Executive Officer)

Co-investorsACACF InvestorsAWAwareness VentureBABailey Venture PartnersINInnovating CapitalJLJLSLILifeSci Venture Partners+3 more

Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer.

BiotechHealthtechExton, US

SKScott K. Dessain(Executive Officer, Director)inDennis H Giesing(Executive Officer)inCRCorleen Roche(Executive Officer)inMichael J Morin(Executive Officer)PSPurnanand Sarma(Executive Officer, Director)inGeorge Hobbs(Executive Officer)

Co-investorsBIBioAdvanceDEDelaware Crossing Investor GroupEVEvolution VC PartnersMIMilitia Hill VenturesRORobin Hood VenturesT.T. Rowe Price

A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.

BiotechHealthtechNew York, US

ZPZachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)

Co-investorsPOPontifax Venture CapitalTATarnagulla VenturesVIVida VenturesTCTCG Crossover

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)James Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVSVishwas Setia(Executive Officer)inChristopher A. Kroeger(President, Chief Executive Officer and Director)

Co-investorsAVAvego BioScience CapitalFOForbionNONovo Holdings

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPDEDeerfield Management CompanyFOForesite CapitalFRFrazier Life SciencesGEGeneral Catalyst+9 more

Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.

BiotechHealthtechNew Haven, US

SUStephen Uden(Founder)inMWMartin W. Mackay(Chairman of the Board of Directors)inJon(Chief Financial Officer)

Co-investors5A5AM VenturesCACanaan PartnersCOConnecticut InnovationsF-F-Prime CapitalMIMitsui Global InvestmentSOSolasta Ventures+2 more

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.

BiotechHealthtechNew Haven, US

Thomas Sciascia(Executive Officer)JGJennifer Good(Co-Founder, President and CEO)inTSThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)LDLisa Delfini(Executive Officer)inWFWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in

Co-investorsAPAPERTURE Venture PartnersFRFrazier Life SciencesNENew Enterprise Associates (NEA)VIViking GlobalOMOmega Funds

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

William Charles Banyai(Executive Officer, Director, Promoter)BJBill James Peck(Executive Officer, Promoter)ELEmily Leproust(Founder)inEmily Leproust, PhD(CEO and Co-Founder of Twist)PFPatrick Finn(President and Chief Operating Officer)inALAdam Laponis(Chief Financial Officer)in

Co-investors+N+ND Capital3E3E Bioventures CapitalARARCH Venture PartnersASAsset Management CompanyATATEL VenturesBABay City Capital+10 more

Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates.

BiotechHealthtech

GPGrant Pickering(Chief Executive Officer, Director and Co-Founder)inJeff Fairman(Vice President of Research and Co-Founder)

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesLOLongitude CapitalRARA Capital+3 more

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LOLEON O. MOULDER, JR.(Director)LMLonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HMHUA MU(Executive Officer, Director)in

BoardPGPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsDEDelos CapitalLOLongitude CapitalNENew Enterprise Associates (NEA)NONorwest Venture PartnersQUQuan CapitalSRSR One Capital Management+3 more

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsFOForesite CapitalLOLongwood FundNONorwest Venture PartnersRIRiverVest Venture PartnersYSYsios CapitalEIEight Roads Ventures+3 more

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

WWWilliam Wei Caoin

Co-investorsLALAVLILilly Asia VenturesOROrbiMedEXExome Asset ManagementJAJanus Henderson InvestorsRARA Capital+3 more

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

AI & Machine LearningBiotechDeep TechSan Diego, US

Michael Martin, Ph.D.(Chief Executive Officer, President)JFJorge F. DiMartinoinMMMichael Martin(President, Chief Executive Officer)inSMStephen Mullennix(Executive Officer)inSerge Messerlian, M.Sc., M.B.A.(Chief Executive Officer)

BoardSMSerge Messerlian(Director)in

Board seatRHRob Hopfner· per SEC Form D

Co-investorsAMaMoonCRCRV (Charles River Ventures)DCDCVC (Data Collective)M M VenturesNENeotribe VenturesSOSoftBank Vision Fund+3 more

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.

BiotechHealthtechSouth San Francisco, US

KCKathleen Collins(Director)inLKLawrence Kong(Executive Officer)inRPRon Park(President & CEO)inFGFrancine Gregoire(Chief Scientific Officer)inPPPriya Parameswaran(Chief Business Officer)in

BoardJPJayson Punwani(Director)in

Co-investorsBEBEVCSRSR One Capital ManagementABAbingworth

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEMEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesECEcoR1 CapitalNENew Enterprise Associates (NEA)RARA CapitalSOSofinnova VenturesCOCowen Healthcare Investments+2 more

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Leonid Beigelman(President)inLMLawrence M. Blatt(Chairman, President, & Chief Executive Officer; co-founder)inHAHardean Achneck(Executive Officer)inBDBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)inJSJulian Symons(Executive Vice President, Chief Scientific Officer)in

Co-investorsRORoche Venture FundWEWellington ManagementVIVivo Capital

HealthtechSaratoga Springs, US

DTDaniel T. Pickett III(Executive Officer, Director)Timothy Koehler(Executive Officer)Greg Stephen(Executive Officer)

BoardHolly Benson(Director)Mary Langowski(Director)Peter Dorsman(Director)

Co-investorsCLClaritas CapitalWHWhat If VenturesOLOlive Tree VenturesTATakeda VenturesVIVista Equity Partners

Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.

Enterprise SoftwareFintechSaaS

Bill Ward(Chief Executive Officer)

Co-investorsACAcies InvestmentsALAloft VCALAlta PartnersAMAmity VenturesARArtis VenturesASAsymmetric Capital Partners+21 more

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsATAtlas VentureMIMission BiocapitalPFPfizer Venture InvestmentsPFPfizer Ventures

DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.

BiotechDigital HealthMedical DevicesBoston, US

RBRobert Brucker(Executive Officer)inKRKarl R. Beutner(Executive Officer, Director)inNENichola Eliovits(Executive Officer, Director)inMDMax Dawson(Executive Officer)in

BoardWRWilder Ramsey(Director)inJennifer Lee(Director)

Co-investorsCICivilization Ventures Management, LlcJOJoyance PartnersOLOlive Tree CapitalSTStart CapitalTOToba CapitalVAValia Ventures+2 more

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

LPLuis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Co-investorsANAndera PartnersAVAvego BioScience CapitalB B Capital GroupB4B4 CapitalBEBeiersdorf Innovation FundFEFemHealth Ventures+4 more

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

JVJohn Valliant(Founder)in

Co-investorsFAFACIT (Fight Against Cancer Innovation Trust)GEGenesys CapitalHEHealthCapLULumira VenturesSESeroba Life SciencesVEVenture Ontario+6 more

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

BoardBBBruce Booth(Chairman)in

Co-investorsATAtlas VentureB B Capital GroupB4B4 CapitalMRMRL Ventures FundSOSofinnova PartnersSOSolasta Ventures+2 more

BiotechBoston, US

ABAxel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)

BoardEdward Mathers(Director)RHRob Hopfner(Director)inMartin Edwards(Director)

Co-investorsLOLongitude CapitalNENew Enterprise Associates (NEA)SASanofi VenturesSOSofinnova Ventures

IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.

BiotechMedical Devices

Dr. Dhingra

Co-investorsAVAvoro Capital AdvisorsEIEIR VenturesKUKurma PartnersRARA CapitalSASamsara BioCapitalSUSunstone Capital+3 more

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsARARCH Venture PartnersSOSofinnova VenturesALAlexandriaPUPureTech HealthWEWellcome Trust

MapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.

AI & Machine LearningBiotechHealthtechMedical Devices

CKChristopher Kroeger, M.D.(Chief Executive Officer, Founder, Board Member)Karl Deisseroth, M.D., Ph.D.(Founder, Scientific Advisory Board)Robert Malenka, M.D., Ph.D.(Founder, Board Member, Scientific Advisory Board)Christopher Kroeger(Founder)Karl Deisseroth(Founder)Karoly Nikolich(Founder)

Co-investorsAVAvego BioScience CapitalFOForbion

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.

BiotechDigital HealthHealthtechMedical Devices

Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)

BoardDavid White(Sleep Medicine Advisor)

Co-investorsBRBroadview VenturesNONorwest Venture PartnersSUSupermoon CapitalFOForbionHTHTGFINInkef

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.

BiotechHealthtechMedical DevicesBoston, CH

RSRiad Sherif(Chief Executive Officer)in

Co-investorsBABay City CapitalBRBrunnur Ventures GPVIVI PartnersBVBVCF

San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.

BiotechSan Diego, US

David S. Mullarkey(Executive Officer, Director)AOArnold Oliphant(Executive Officer)inKSKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)

Co-investorsARARCH Venture PartnersATATEL VenturesDCDCVC (Data Collective)DEDecheng CapitalLALam CapitalALALTITUDE LIFE SCIENCE VENTURES+3 more

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDCDP Venture CapitalIRIreland Strategic Investment FundADAdams Street PartnersGEGenesys CapitalHEHealthCapOROrbiMed+1 more

Vericel manufactures and markets advanced cell therapy products for sports medicine and severe burn care, and holds an exclusive North American license for NexoBrid.

BiotechHealthtechMedical Devices

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

IMIvana Magovcevic-Liebisch(Executive Officer, Director)CVChristopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Co-investorsATAtlas VentureHAHatteras Venture PartnersLILightstone VenturesVIVida VenturesLOLongwood Fund

Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.

AI & Machine LearningData & InfrastructureDefense TechTel Aviv

Amiad Daniel(Executive Officer, Director)MPMatan Peled(Founder)inAmi Daniel(Founder)

BoardDov Gatmon(Director)Patrick Poon(Director)ESEden Shochat(Director)in

Co-investorsALAlephFTFTV CapitalTHThompson Hutton, LLCJAJanus Henderson InvestorsQIQiming Venture PartnersQUQuan Capital+3 more

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOROrbiMedQUQuan CapitalRARA CapitalSASanofi VenturesSRSR One Capital ManagementJAJanus Henderson Investors+3 more